Literature DB >> 22354002

Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.

Alexandra J Greenberg1, S Vincent Rajkumar, Celine M Vachon.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), is one of the most common premalignant conditions in the general population. The cause of MGUS is largely unknown. Recent studies show that there is an increased prevalence of MGUS in blood relatives of persons with lymphoproliferative and plasma cell proliferative disorders, suggesting presence of shared underlying genetic influences. In the past few years, additional studies have examined risk factors and biologic characteristics that may contribute to the increased prevalence of MGUS among relatives of probands with MGUS, MM, and other blood malignancies. This article reviews the known epidemiology and risk factors for familial MGUS and myeloma, the risk of lymphoproliferative disorders and other malignancies among blood-relatives of patients with MGUS and MM, and discusses future directions for research.

Entities:  

Mesh:

Year:  2012        PMID: 22354002      PMCID: PMC3369675          DOI: 10.1182/blood-2011-11-387324

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Alexandra Wikowicz; Evangelos Terpos; Marita Ziepert; Diana Nikolaus; Yin Yang; Natalie Fadle; Evi Regitz; Meletios A Dimopoulos; Steven P Treon; Zachary R Hunter; Michael Pfreundschuh
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

2.  Variation in innate immunity genes and risk of multiple myeloma.

Authors:  Mark P Purdue; Qing Lan; Idan Menashe; Tongzhang Zheng; Yawei Zhang; Meredith Yeager; H Dean Hosgood; Shelia H Zahm; Stephen J Chanock; Nathaniel Rothman; Dalsu Baris
Journal:  Hematol Oncol       Date:  2011-03       Impact factor: 5.271

3.  Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Stephan Thome; Dennis D Weisenburger; Vinetta Witt; Jane Lynch; Florian Zettl; Lorenz Trümper; Natalie Fadle; Evi Regitz; Henry Lynch; Michael Pfreundschuh
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

Review 4.  Familial multiple myeloma: a family study and review of the literature.

Authors:  H T Lynch; W G Sanger; S Pirruccello; B Quinn-Laquer; D D Weisenburger
Journal:  J Natl Cancer Inst       Date:  2001-10-03       Impact factor: 13.506

5.  Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Manfred Ahlgrimm; Natalie Fadle; Evi Regitz; Claudia Pfoehler; Niels Murawski; Michael Pfreundschuh
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study.

Authors:  M Eriksson; B Hållberg
Journal:  Cancer Causes Control       Date:  1992-01       Impact factor: 2.506

8.  Multiple myeloma in three siblings.

Authors:  L J Horwitz; R N Levy; F Rosner
Journal:  Arch Intern Med       Date:  1985-08

9.  Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.

Authors:  H Dean Hosgood; Dalsu Baris; Yawei Zhang; Sonja I Berndt; Idan Menashe; Lindsay M Morton; Kyoung-Mu Lee; Meredith Yeager; Shelia H Zahm; Stephen Chanock; Tongzhang Zheng; Qing Lan
Journal:  Leuk Res       Date:  2009-04-11       Impact factor: 3.156

10.  Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

View more
  26 in total

Review 1.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

2.  Risk factors for monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Maira A Castaneda-Avila; Christine M Ulbricht; Mara Meyer Epstein
Journal:  Ann Hematol       Date:  2021-01-08       Impact factor: 3.673

3.  Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Authors:  Elad Ziv; Eric Dean; Donglei Hu; Alessandro Martino; Daniel Serie; Karen Curtin; Daniele Campa; Blake Aftab; Paige Bracci; Gabriele Buda; Yi Zhao; Jennifer Caswell-Jin; Robert Diasio; Charles Dumontet; Marek Dudziński; Laura Fejerman; Alexandra Greenberg; Scott Huntsman; Krzysztof Jamroziak; Artur Jurczyszyn; Shaji Kumar; Djordje Atanackovic; Martha Glenn; Lisa A Cannon-Albright; Brandt Jones; Adam Lee; Herlander Marques; Thomas Martin; Joaquin Martinez-Lopez; Vincent Rajkumar; Juan Sainz; Annette Juul Vangsted; Marzena Wątek; Jeffrey Wolf; Susan Slager; Nicola J Camp; Federico Canzian; Celine Vachon
Journal:  Nat Commun       Date:  2015-07-22       Impact factor: 14.919

4.  Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.

Authors:  Klaus-Dieter Preuss; Michael Pfreundschuh; Martin Weigert; Natalie Fadle; Evi Regitz; Boris Kubuschok
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

5.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

6.  Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.

Authors:  Leah H Schinasi; Elizabeth E Brown; Nicola J Camp; Sophia S Wang; Jonathan N Hofmann; Brian C Chiu; Lucia Miligi; Laura E Beane Freeman; Silvia de Sanjose; Leslie Bernstein; Alain Monnereau; Jacqueline Clavel; Guido J Tricot; Djordje Atanackovic; Pierluigi Cocco; Laurent Orsi; James A Dosman; John R McLaughlin; Mark P Purdue; Wendy Cozen; John J Spinelli; Anneclaire J de Roos
Journal:  Br J Haematol       Date:  2016-06-22       Impact factor: 6.998

7.  Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  A J Greenberg; A M Lee; D J Serie; S K McDonnell; J R Cerhan; M Liebow; D R Larson; C L Colby; A D Norman; R A Kyle; S Kumar; S V Rajkumar; R B Diasio; S L Slager; C M Vachon
Journal:  Leukemia       Date:  2012-08-16       Impact factor: 11.528

8.  Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.

Authors:  Rosalie Griffin Waller; Robert J Klein; Joseph Vijai; James D McKay; Alyssa Clay-Gilmour; Xiaomu Wei; Michael J Madsen; Douglas W Sborov; Karen Curtin; Susan L Slager; Kenneth Offit; Celine M Vachon; Steven M Lipkin; Charles Dumontet; Nicola J Camp
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

Review 9.  Incorporating novel agents in the management of elderly myeloma patients.

Authors:  Tommasina Guglielmelli; Antonio Palumbo
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 4.213

10.  Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.

Authors:  Alexandra J Greenberg; Margot Cousin; Shaji Kumar; Rhett P Ketterling; Ryan A Knudson; Dirk Larson; Colin Colby; Christopher Scott; Celine M Vachon; S Vincent Rajkumar
Journal:  Eur J Haematol       Date:  2013-07-22       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.